SimBioSys, a precision medicine company using artificial intelligence to improve cancer care, announced that its FDA-cleared TumorSight Viz technology was recently featured on ABC News Digital and Good Morning America. The coverage highlighted how AI-powered 3D visualization helps surgeons and patients make more informed decisions about breast cancer surgery.
Health Technology Insights: Cohere Health Launches AI Prior Authorization Tool
The segment followed patient Brooke Davis and her care team at Mercy Cedar Rapids, led by Dr. Vincent Reid, MD, FACS, Chairman of Surgery. Using TumorSight Viz, the team applied AI analysis to Brooke’s breast MRI scans to measure tumor size, shape, and spatial relationships with surrounding tissue. This process allowed them to evaluate breast-conserving surgical options. Dr. Darien Sutton, ABC News Medical Correspondent, narrated the segment, emphasizing the role of this technology in patient-centered care during Breast Cancer Awareness Month.
Stacey Stevens, President and CEO of SimBioSys, said the coverage reflects the company’s mission to provide clinicians with clearer insights and patients with greater confidence in their treatment decisions. She explained that TumorSight Viz gives surgeons detailed visualizations of tumors, helping hospitals deliver precise care while empowering patients to better understand their options.
Health Technology Insights: Dermatology of Miami Adds Dr. George Glinos to Team
Dr. Vincent Reid noted that TumorSight Viz allowed the team to confirm that a breast-conserving surgery was feasible for Brooke while ensuring a favorable cosmetic outcome. He added that the technology has fundamentally changed how surgeons plan procedures and communicate with patients about their treatment options, improving both accuracy and confidence.
The feature also highlighted the collaboration between SimBioSys and NVIDIA, whose computing platforms and MONAI framework support AI training and validation for TumorSight Viz. Kimberly Powell, Vice President of Healthcare at NVIDIA, said this partnership allows SimBioSys to create digital tumor models that give clinicians powerful tools to personalize treatment and improve patient outcomes.
TumorSight Viz transforms conventional breast MRI scans into comprehensive 3D models. It automatically analyzes tumor characteristics and their spatial relationships within the breast, providing surgeons with deeper anatomical insight. This enables more precise, confident, and personalized planning for breast-conserving surgery.
Health Technology Insights: Town Hall Ventures Closes $440Million Fund to Boost AI Healthcare Access
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
